Healthcare IT and Services

Karo Bio

December 2010


A rights share issue providing SEK 300 million for funding a phase III trial of the Company´s main development project, eprotirome.


Karo Bio is a Swedish pharmaceutical company which since 1986 has focused on the nuclear receptor area generating an innovative project pipeline. The leading compound eprotirome enters clinical phase III development as a dyslipidemia drug with strong phase II data and a unique mechanism of action.


A public company listed on Nasdaq Small Cap OMX.